Blood pressure, left ventricular geometry, and systolic function in children exposed to inorganic arsenic

Environmental Health Perspectives

Volumn 123, Issue 6, 2015, Pages 629-635

  Osorio Yáñez, Citlalli ^a   Ayllon Vergara, Julio C ^b   Arreola Mendoza, Laura ^c   Aguilar Madrid, Guadalupe ^d   Hernández Castellanos, Erika ^a   Sánchez Peña, Luz C ^a   Del Razo, Luz M ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b HOSPITAL ESPAÑOL DE MÉXICO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; GLUCOSE; NITRIC OXIDE; DRINKING WATER; ORGANOARSENIC DERIVATIVE;

AORTIC ROOT DIAMETER; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD PRESSURE; CARDIOVASCULAR PARAMETERS; CHILD; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HUMAN; INTERVENTRICULAR SEPTUM THICKNESS IN DIASTOLE; LEFT ATRIAL DIAMETER; LEFT ATRIUM DIAMETER; LEFT VENTRICULAR END SYSTOLIC VOLUME; LEFT VENTRICULAR INTERNAL DIASTOLIC DIAMETER; LEFT VENTRICULAR INTERNAL SYSTOLIC DIAMETER; LEFT VENTRICULAR SHORTENING FRACTION; MALE; MITRAL E DECELERATION TIME; POSTERIOR WALL THICKNESS IN DIASTOLE; PRESCHOOL CHILD; PRIORITY JOURNAL; RELATIVE WALL THICKNESS; SYSTOLE; SYSTOLIC BLOOD PRESSURE; URINALYSIS; ARSENIC POISONING; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; HEART VENTRICLE; MEXICO; PATHOLOGY; URINE;

ARSENIC POISONING; ARSENICALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRINKING WATER; ECHOCARDIOGRAPHY; ENVIRONMENTAL EXPOSURE; FEMALE; HEART VENTRICLES; HUMANS; MALE; MEXICO; SPECTROPHOTOMETRY, ATOMIC;

EID: 84930508702     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1307327     Document Type: Article

References (46)

1. American Conference of Governmental Industrial Hygienists. 2004. Arsenic and Soluble Inorganic Compounds: BEI®. 8th Edition Documentation. Publication 7DOC-665. Cincinnati, OH:American Conference of Governmental Industrial Hygienists.
2. Armienta MA, Rodríguez R, Cruz O. 1997. Arsenic content in hair of people exposed to natural arsenic polluted groundwater at Zimapán, México. Bull Environ Contam Toxicol 59(4):583–589.
3. Artham SM, Lavie CJ, Milani RV, Patel DA, Verma A, Ventura HO. 2009. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis 52(2):153–167.
4. Baguet JP, Minville C, Tamisier R, Roche F, Barone- Rochette G, Ormezzano O, et al. 2011. Increased aortic root size is associated with nocturnal hypoxia and diastolic blood pressure in obstruc-tive sleep apnea. Sleep 34(11):1605–1607.
5. Centers for Disease Control and Prevention. 2000. Growth Charts. Available: http://www.cdc.gov/growthcharts [accessed 26 June 2011].
6. Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, et al. 1995. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25(1):53–60.
7. Chiou HY, Huang WI, Su CL, Chang SF, Hsu YH, Chen CJ. 1997. Dose-response relationship between preva-lence of cerebrovascular disease and ingested inorganic arsenic. Stroke 28(9):1717–1723.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6):1206–1252.
9. Cortas NK, Wakid NK. 1990. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 36(8 pt 1):1440–1443.
10. Cuspidi C, Rescaldani M, Sala C. 2013. Prevalence of echocardiographic left-atrial enlargement in hypertension: a systematic review of recent clinical studies. Am J Hypertens 26(4):456–464.
11. Daniels SR, Kimball TR, Morrison JA, Khoury P, Meyer RA. 1995. Indexing left ventricular mass to account for differences in body size in children and adolescents without cardiovascular disease. Am J Cardiol 76(10):699–701.
12. Davidson R, MacKinnon JG. 1993. Estimation and Inference in Econometrics. New York:Oxford University Press.
13. Dhuper S, Abdullah RA, Weichbrod L, Mahdi E, Cohen HW. 2011. Association of obesity and hyper-tension with left ventricular geometry and function in children and adolescents. Obesity (Silver Spring) 19(1):128–133.
14. Farrance I. 1987. Plasma glucose methods, a review. Clin Chem Rev 8:55–68.
15. Gupta P, Nagaraju SP, Gupta A, Mandya Chikkalingaiah KB. 2012. Prehypertension—time to act. Saudi J Kidney Dis Transpl 23(2):223–233.
16. Hawkesworth S, Wagatsuma Y, Kippler M, Fulford AJ, Arifeen SE, Persson LA, et al. 2013. Early exposure to toxic metals has a limited effect on blood pressure or kidney function in later childhood, rural Bangladesh. Int J Epidemiol 42(1):176–185.
17. Hernández-Zavala A, Matoušek T, Drobná Z, Paul DS, Walton F, Adair BM, et al. 2008a. Speciation analysis of arsenic in biological matrices by auto-mated hydride generation-cryotrapping-atomic absorption spectrometry with multiple microflame quartz tube atomizer (multiatomizer). J Anal At Spectrom 23:342–351.
18. Hernández-Zavala A, Valenzuela OL, Matoušek T, Drobná Z, Dĕdina J, García-Vargas GG, et al. 2008b. Speciation of arsenic in exfoliated urinary bladder epithelial cells from individuals exposed to arsenic in drinking water. Environ Health Perspect 116:1656–1660; doi:10.1289/ehp.11503.
19. Hirth A, Edwards NC, Greve G, Tangeraas T, Gerdts E, Lenes K, et al. 2012. Left ventricular function in children and adults after renal transplantation in childhood. Pediatr Nephrol 27(9):1565–1574.
20. Hsueh YM, Wu WL, Huang YL, Chiou HY, Tseng CH, Chen CJ. 1998. Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis 141(2):249–257.
21. Jiang JJ, Chen XF, Liu XM, Tang LJ, Lin XF, Pu ZX, et al. 2009. Aortic root dilatation is associated with carotid intima-media thickness but not with carotid plaque in hypertensive men. Acta Cardiol 64(5):645–651.
22. Le XC, Ma M. 1998. Short-column liquid chromatog-raphy with hydride generation atomic fluores-cence detection for the speciation of arsenic. Anal Chem 70(9):1926–1933.
23. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. 2002. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349):1903–1913.
24. Li X, Li B, Xi S, Zheng Q, Wang D, Sun G. 2013. Association of urinary monomethylated arsenic concentration and risk of hypertension: a crosssectional study from arsenic contaminated areas in northwestern China. Environ Health 12:37; doi:10.1186/1476-069X-12-37.
25. Lilly LS. 2011. Pathophysiology of Heart Disease. 5th ed. Baltimore, MD:Wolters Kluwer/Lippincott Williams & Wilkins.
26. Masugata H, Senda S, Murao K, Okuyama H, Inukai M, Hosomi N, et al. 2011. Aortic root dilatation as a marker of subclinical left ventricular diastolic dysfunction in patients with cardiovascular risk factors. J Int Med Res 39(1):64–70.
27. Mumford JL, Wu K, Xia Y, Kwok R, Yang Z, Foster J, et al. 2007. Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study. Environ Health Perspect 115:690–694; doi:10.1289/ehp.9686.
28. National High Blood Pressure Education (NHBPE) Program Working Group on High Blood Pressure in Children and Adolescents. 2004. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114(2 suppl 4th Report):555–576.
29. Osorio-Yáñez C, Ayllon-Vergara JC, Aguilar-Madrid G, Arreola-Mendoza L, Hernández-Castellanos E, Barrera-Hernández A, et al. 2013. Carotid intima- media thickness and plasma asymmetric dimethylarginine in Mexican children exposed to inorganic arsenic. Environ Health Perspect 121:1090–1096; doi:10.1289/ehp.1205994.
30. Poręba R, Gać P, Poręba M, Mazur G. 2013. Echocardiographic assessment of myocardial function in workers occupationally exposed to lead without clinically evident heart disease. Environ Toxicol Pharmacol 36(2):522–528.
31. Redwine KM, Falkner B. 2012. Progression of prehyper-tension to hypertension in adolescents. Curr Hypertens Rep 14(6):619–625.
32. Sahn DJ, DeMaria A, Kisslo J, Weyman A. 1978. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58(6):1072–1083.
33. Sanchez-Soria P, Broka D, Monks SL, Camenisch TD. 2012. Chronic low-level arsenite exposure through drinking water increases blood pressure and promotes concentric left ventricular hypertrophy in female mice. Toxicol Pathol 40(3):504–512.
34. Saydah SH, Pavkov ME, Zhang C, Lacher DA, Eberhardt MS, Burrows NR, et al. 2013. Albuminuria prevalence in first morning void compared with previous random urine from adults in the National Health and Nutrition Examination Survey, 2009–2010. Clin Chem 59(4):675–683.
35. Schwenk M, Gundert-Remy U, Heinemeyer G, Olejniczak K, Stahlmann R, Kaufmann W, et al. 2003. Children as a sensitive subgroup and their role in regulatory toxicology: DGPT workshop report. Arch Toxicol 77(1):2–6.
36. Smith AH, Yunus M, Khan AF, Ercumen A, Yuan Y, Smith MH, et al. 2013. Chronic respiratory symptoms in children following in utero and early life exposure to arsenic in drinking water in Bangladesh. Int J Epidemiol 42(4):1077–1086.
37. Srivastava S, D’Souza SE, Sen U, States JC. 2007. In utero arsenic exposure induces early onset of atherosclerosis in ApoE–/–mice. Reprod Toxicol 23(3):449–456.
38. Sun G, Xu Y, Li X, Jin Y, Li B, Sun X. 2007. Urinary arsenic metabolites in children and adults exposed to arsenic in drinking water in inner Mongolia, China. Environ Health Perspect 115:648–652; doi:10.1289/ehp.9271.
39. Tseng WP. 1977. Effects and dose–response relation-ships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 19:109–119.
40. Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG, Cruz-Gonzalez MB, Garcia-Montalvo EA, Calderon-Aranda ES, et al. 2005. Urinary trivalent methylated arsenic species in a population chroni-cally exposed to inorganic arsenic. Environ Health Perspect 113:250–254; doi:10.1289/ehp.7519.
41. Valenzuela OL, Drobná Z, Hernández-Castellanos E, Sánchez-Peña LC, García-Vargas GG, Borja- Aburto VH, et al. 2009. Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions. Toxicol Appl Pharmacol 239(2):200–207.
42. Verdecchia P, Angeli F, Achilli P, Castellani C, Broccatelli A, Gattobigio R, et al. 2007. Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events? Curr Opin Cardiol 22(4):329–334.
43. Wang CH, Hsiao CK, Chen CL, Hsu LI, Chiou HY, Chen SY, et al. 2007. A review of the epidemiologic literature on the role of environmental arsenic exposure and cardiovascular diseases. Toxicol Appl Pharmacol 222(3):315–326.
44. Wang CH, Jeng JS, Yip PK, Chen CL, Hsu LI, Hsueh YM, et al. 2002. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation 105(15):1804–1809.
45. Wu MM, Chiou HY, Hsueh YM, Hong CT, Su CL, Chang SF, et al. 2006. Effect of plasma homocys-teine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid athero-sclerosis. Toxicol Appl Pharmacol 216(1):168–175.
46. Yuan Y, Marshall G, Ferreccio C, Steinmaus C, Selvin S, Liaw J, et al. 2007. Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950–2000. Am J Epidemiol 166(12):1381–1391.